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Structured abstract 20 
Background—Chitosan and alkalinizing agentscan decrease morbidity and mortality 21 
concentrationsin humans with chronic kidney disease (CKD). Whether this holds true in dogs is not 22 
known. 23 
Objective—To determine whether two commercial dietary supplements containing chitosan and 24 
alkalinizing agents (Renal
®
) or flavonoids and probiotics (Renal advanced
®
), compared to placebo, 25 
reduce mortality rate due to uremic crises in dogs with spontaneous CKD, fed a renal diet. 26 
Design—Masked, randomized, controlled clinical trial. 27 
Animals—43 dogs with spontaneous CKD in IRIS stages ≥ 2, fed a renal diet. 28 
Procedure—Dogs were randomly allocated to receive placebo (group A), Renal® (group B), or 29 
Renal
®
 plus Renal advanced
®
 (group C). During a first 4-week period all dogs were fed a renal diet 30 
and then randomized and clinically evaluated up to 44 weeks. The effects of dietary supplements on 31 
mortality rate due to uremic crises were assessed. 32 
Results—Compared to group A, dogs in group B and C had approximately 50% lower mortality 33 
rate due to uremic crises (p=0.038 and p=0.041, respectively); differences were not observed 34 
between group B and C. Three dogs in group B and 3 in group C had a reduction in serum urea and 35 
creatinine concentrations after 16-20 weeks of treatment. 36 
Conclusions and Clinical Relevance—Dietary supplementation with chitosan and alkalinizing 37 
agents along with a renal diet is beneficial in reducing mortality rate in dogs with spontaneous CKD 38 
in IRIS stages ≥ 2, and reduces concentrations of serum urea and creatinine in some dogs. The 39 
dietary supplement may lessens progression of renal failure in CKD dogs. 40 
 41 
Key words – dog, CKD, renal diet, death, uremic crisis. 42 
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Introduction 44 
There is a consensus to use dietary modification in dogs affected by chronic kidney disease 45 
(CKD).
1-7
 Feeding a renal diet (RD) in dogs with mild and moderate spontaneous CKD had 46 
beneficial effects on uremia and mortality rate compared to a maintenance diet.
1
 In addition, 47 
phosphate retention and renal secondary hyperparathyroidism are common complications of CKD,
2-
48 
7 
and hyperphosphatemia is associated with the development of renal lesions in dogs and cats.
2-7
 In 49 
humans and cats, oral supplementation with compounds such as chitosan (produced by 50 
deacetylation of chitin, which is the structural element in the exoskeleton of crustaceans and cell 51 
wall of fungi), calcium carbonate, aluminium hydroxide, and potassium citrate has been advocated 52 
to control hyperphosphatemia and to reduce azotemia during spontaneous CKD.
4-11
 Laboratory and 53 
clinical studies in cats have demonstrated a renoprotective effect of dietary phosphate restriction 54 
with chitosan.
10
 However, whether this holds true for dogs has not been assessed. Aim of the 55 
present study was to evaluate the efficacy of two commercial oral supplements rich in chitosan, 56 
enteric phosphate binders and alkalinizing agents (Renal
®
)
 a
, or rich in flavonoids, probiotics, 57 
prebiotics and vitamin (Renal advanced
®
)
 a
, in reducing mortality rate related to uremic crises in 58 
dogs affected by spontaneous CKD in IRIS stages 2, 3 and 4,
4,12
 fed a RD. 59 
60 
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Materials and Methods 61 
Animals 62 
Dogs with CKD were recruited at the Clinica Veterinaria Pirani of Reggio Emilia, Italy. Results of 63 
history, physical examinations, including body weight (BW) and body condition score (BCS) using 64 
a 1 to 5 scoring system (3 optimal), CBC, serum biochemical profile, urinalysis, urine protein-to-65 
creatinine (UPC) ratio, hemogasanalysis, and indirect blood pressure measurements were collected. 66 
All dogs underwent abdominal ultrasonographic examination, which was performed by the same 67 
operator (AZ) and with the same instrument
e
. Dogs of any age were included if presenting stable 68 
renal function, as defined by serum creatinine concentrations above 1.4 mg/dL (International Renal 69 
Interest Society (IRIS) Staging System ≥ 2) that did not increase or decrease by 15% or more within 70 
4 weeks from initial determination.
4
 In the first 4-week period all dogs were started on a RD
b,c
. 71 
Dogs were excluded if affected by inflammation or infection of the genitourinary tract, cardiac 72 
disease, neoplasia and endocrinopathies. As a standard, dogs with arterial pressure (AP) substage 3 73 
of the IRIS Staging System
12
 were treated with oral amlodipine at 0.1 to 0.5 mg/kg, q24h, in order 74 
to reduce AP to substage 1 or 0.
2-7,13,14
 Dogs with serum albumin concentration ≤ 2.0 g/dL received 75 
oral acetylsalicylic acid at 2.0 mg/kg, q24h, to prevent thrombosis.
4-7 
76 
 77 
Study design 78 
A randomized, masked, controlled clinical trial was performed using a software to allocate cases.
d
 79 
Informed consent to participate in the study was signed by dog owners. 80 
Following inclusion, all dogs started a RD
b,c
. After 4 weeksdogs were clinically re-evaluated, 81 
performing all above laboratory and instrumental analyses, and assigned to group A (placebo), or 82 
treatment groups B (Renal
®
) or C (Renal
® 
plus Renal advanced
®
); composition of the dietary 83 
supplements is provided in Table 1. 84 
To mask the identity of the 3 supplements, they were formulated as powders with identical colours 85 
and contained in the same package. After assignment to group A, B or C, dogs were reassessed 86 
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between week 4 and 8. Thereafter, examinations were scheduled every 4 months and up to 44 87 
weeks of treatment, or earlier if worsening of clinical signs was noted by the owner.  88 
 89 
Blood sampling and assay 90 
During each examination a blood sample was collected in overnight fasted dogs, and serum was 91 
obtained within 30 minutes, stored at 4°C and analyzed within 24 hours. Hemogasanalysis
f
 was 92 
immediately performed in all cases. 93 
CBC
g
 and serum biochemical analysis, including albumin, total proteins, glucose, bilirubin, 94 
cholesterol, amylase, alanine transferase, alkaline phosphatase, urea nitrogen, creatinine, ionized 95 
calcium, sodium, potassium, chloride and phosphate, were determined by use of standard methods
 h
. 96 
Blood samples were labelled with alphanumeric codes assigned by randomization to ensure that 97 
laboratory personal were blinded during processing. 98 
 99 
Urine sample and urinalysis 100 
During abdominal ultrasonography, an echo-guided cystocentesis was performed in all dogs, by use 101 
of a 5 mL syringe connected to a 23-gauge needle. All urine samples were put in 10 mL, sterile, 102 
evacuated collection tubes labelled with alphanumeric codes based on the previous randomization. 103 
All urine samples were analyzed by the same operator (FN). Urines were examined within 60 104 
minutes from collection if samples were stored at room temperature (approximately 20°C), or 105 
within 4 hours if samples were stored at 4° to 8°C. Urine sediment was obtained by centrifugation 106 
(10 minutes at 900 × g) of 5 mL of urine, followed by removal of 4.5 mL of supernatant, and by 107 
resuspension of the remaining 0.5 mL of urine. A sample of 12 µL of the resuspended urine was 108 
microscopically assessed. The supernatant was transferred into separate tubes and stored at –20°C 109 
to determine urine protein and creatinine concentration within 7 days. RBCs and WBCs were 110 
expressed as mean number of cells/10 hpf (40 × magnification). Urine sediment with bacteriuria, > 111 
5 RBCs or WBCs/hpf, was considered indicative of active inflammation. 112 
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 113 
UPC ratio 114 
To calculate the UPC ratio, protein concentration (mg/dL) was measured with pyrogallol red, and 115 
creatinine (mg/dL) was measured by use of the Jaffé method in undiluted urine that was thawed 116 
before the analysis
h
. Analytes were measured in an automated spectrophotometer
h
. Dogs were 117 
classified as nonproteinuric, borderline proteinuric, or proteinuric according to the IRIS Staging 118 
System
 
(UPC ratio < 0.2 = nonproteinuric, UPC ratio 0.2 to 0.5 = borderline proteinuric, and UPC 119 
ratio > 0.5 = proteinuric).
4,12 
120 
 121 
Blood pressure measurement 122 
Systolic blood pressure measurements were obtained by use of an ultrasonic Doppler device
i
 in all 123 
dogs.
13,14 
124 
 125 
Diagnosis of uremic crisis 126 
Diagnosis of uremic crisis was established by clinicians involved in patient management unaware of 127 
the supplement being administered. Uremic crisis was defined when all of the 3 following findings 128 
were observed: i) identification of at least 2 clinical signs consistent with uremia including 129 
depression, lethargy, anorexia, vomiting, uremic breath odour, or uremic stomatitis; ii) serum urea 130 
nitrogen concentration at least 20% greater than the previously determined value; and iii) no 131 
plausible alternative for these clinical signs.
1 
132 
 133 
Establishing cause of death 134 
Causes of death were categorized as non-renal, probably renal, or renal based on results of 135 
anamnesis, physical examination, blood and urine tests, and criteria used to define uremic crisis. To 136 
avoid bias, only dogs classified in the third category were considered to have died from a renal 137 
event (uremic crisis). Necropsies were not performed in any case. 138 
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 139 
Statistical analysis 140 
Dog characteristics were compared at the time of group assignment and during re-examination 141 
using the Mann-Whitney nonparametric test. Kaplan-Meier followed by log rank test was used to 142 
compare rates of death due to uremic crisis between groups. In addition, the Cox proportional 143 
hazard regression model was used to evaluate the effect of oral supplementation on the relative risk 144 
(RR) of developing death related to uremic crisis. Statistical analysis was performed with a 145 
commercial software
l
, using the intention-to-treat principle. Significance was defined as p<0.05. 146 
147 
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Results 148 
Dogs and groups 149 
Forty-three dogs were enrolled in the study, with a mean age of 5 years (range: 10 months-13 150 
years). Five dogs were intact females, 22 were spayed females, 15 were males and 1 was a castrated 151 
male. Eight dogs were mixed breed, 3 each Dalmatian and German Shepherd, 2 each American 152 
Pittbull, Beagle, Boxer, Cavalier King Charles Spaniel, Dobermann, Golden Retriever, Labrador 153 
Retriever, Rottweiler and Shih-Tzu, and one each Bernese Mountain, Border Collie, Bullmastiff, 154 
English Bulldog, English Cocker, English Setter, Greyhound, Irish Wolfhound, Miniature Poodle, 155 
York-Shire Terrier. Mean BW was 23.3 kg (range: 2.5-71.5). 156 
Fifteen dogs were allocated in group A, 16 in group B, and 12 in group C. At the time of allocation 157 
there was no statistical difference between the groups with regard to signalment, physical 158 
examination findings, and hematological or serum biochemical results. Serum creatinine 159 
concentration of dogs according to the IRIS Staging System is reported in Table 2. 160 
 161 
Follow-up concentrations of creatinine, urea, phosphate, calcium, potassium, bicarbonate, and 162 
results of hemogasanalysis 163 
Mean serum concentrations of creatinine, urea, phosphate and bicarbonate, and results of 164 
hemogasanalysis were all improved in groups B and C when values recorded at 4-8 weeks 165 
following supplement administration were compared with those collected at randomization. 166 
Potassium and calcium remained stable in both group B and C, and no episodes of hyperkalemia or 167 
of hypercalcemia was identified during the study period. There was a significant increase in BW 168 
and BCS in group B and C 4-8 weeks following enrolment (p <0.05). All other parameters included 169 
in the analysis were not different between groups. Of note, 3 dogs in group B and 3 in group C 170 
experienced a reduction of serum urea and creatinine concentrations after 16-20 weeks of treatment 171 
(Figure 1), and maintained stable values at the end of the study; in these dogs body weight did not 172 
decrease. 173 
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 174 
Association between dietary supplements and death 175 
Compared to group A, the use of oral supplements decreased chance of death in both group B 176 
(p=0.038) and C (p=0.041). By the end of the study, 9 out of 15 (60%) dogs in group A were dead, 177 
against 4 out of 16 (25%) in group B and 4 out of 12 (33%) in group C (Table 2); chance of death 178 
was not different between group B and C (p=0.240). 179 
Compared to group A, survival of dogs in group B or in group C was not different. However, 180 
survival of dogs in group B combined with those of group C was significantly longer than in control 181 
dogs (p = 0.042; Logrank test p = 0.008; RR = 0.472; 95%CI: 0.23 – 0.98) (Figure 2). By the end of 182 
the study, 20 out of 28 (72%) dogs in the combined B and C treatment group were alive, compared 183 
to 6 out of 15 (40%) dogs in the control group (Table 2). 184 
Non-renal causes of death included one case of aspiration pneumonia in the treatment group B. 185 
None dog died due to non-renal causes in group C. In group A, one dog died because of 186 
disseminated hemangiosarcoma. The percentage of deaths due to non-renal causes did not differ 187 
between groups. 188 
189 
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Discussion 190 
In a study, admission concentration of serum creatinine did not influence survival in dogs with 191 
spontaneous CKD if a RD was administered.
1
 Indeed, median survival for 21 dogs with a mean 192 
serum creatinine concentration of 3.3 mg/dL was 615 days, and median survival for dogs with 193 
serum creatinine between 2.0 and 3.1 mg/dL was also 615 days. Differently, among 17 dogs fed a 194 
maintenance diet, median survival for dogs with a mean serum creatinine of 3.7 mg/dL was of only 195 
252 days, whereas that of the subpopulation with serum creatinine between 2.0 and 3.1 mg/dL was 196 
461 days.  197 
In the present investigation all dogs were fed a RD, and the mean serum creatinine concentration at 198 
the time of randomization was 5.9, 4.9 and 5.0 mg/dL, in group A, B and C, respectively. Twelve 199 
out of 16 (75%) dogs in group B, and 8 out of 12 (66.6%) in group C were alive after 336 days, 200 
compared to 6 out of 15 (40%) dogs in the group A, suggesting that chitosan together with 201 
alkalinizing agents are useful in maintaining long-term good clinical conditions in dogs, similar to 202 
previous studies performed in humans and cats.
8-11
 The non significant difference observed between 203 
dog groups B and C might be related to the limited period of observation or to a real lack of benefit 204 
of flavonoids, prebiotics and probiotics on renal function in this species. Results of our series 205 
emphasize the efficacy of adding a combination of chitosan, enteric phosphate binders and 206 
alkalinizing agents to RD in reducing death for uremic crises in dogs affected by spontaneous CKD 207 
and azotemic based on the IRIS Staging System (stages ≥ 2; p=0.043). 208 
In addition, of special interest is the reduction in serum creatinine concentration observed after 16-209 
20 weeks of treatment in 6 dogs, 3 each allocated in group B and C (Figure 1). In dogs and cats 210 
affected by CKD, reduction in serum creatinine level is frequently related to hypomiotrophia and 211 
BCS worsening: 6 dogs in the study, in spite of stable or improved BCS respect to initial values, 212 
showed reduction of serum creatinine concentrations. In humans, two possible explanations have 213 
been proposed for the reduction of serum concentrations of nitrogen metabolites, including the 214 
increased clearance of nitrogen metabolites due to compensatory hypertrophy of the remaining 215 
 1
1
 
nephrons, and the enhanced excretion of chitosan bound to nitrogen metabolites in the digestive 216 
tract.
8,15
 Furthermore, it has been reported that chitosan can combine with acidic substances 217 
suspected to be uremic toxins, resulting in their excretion from the body and in clinical 218 
improvementconcentrations.
8,16 
219 
In summary, the present study shows a beneficial effect of a commercial combination of chitosan, 220 
enteric phosphate binders and alkalinizing agents in dogs affected by spontaneous CKD, fed a RD. 221 
The fact that serum urea, creatinine and inorganic phosphate concentrations, and bicarbonate 222 
improved is consistent with the hypothesis that delay in development of uremic crises and 223 
associated mortality rate was related, at least in part, with a reduction in the progression rate of 224 
renal failure. 225 
 226 
Notes 227 
a
 Renal
®
 and Renal advanced
®
 - Istituto Farmaceutico Candioli SpA, Italy. 228 
b
 Hill’s Prescription Diet Canine k/d®, Hill’s Pet Nutrition Inc, Topeka, Kan. 229 
c
 Royal Canin Renal Canine
®
, Royal Canin SA, Aimargues, France. 230 
d
 GraphPad QuickCalcs calculator by GraphPad Software, Inc (2002-2005). 231 
e
 Philips HD11XE or Philips HD7XE, Philips Ultrasound, Bothell, Washington, USA. 232 
f
 Rapidpoint
®
 400, Bayer Health Care, Tarrytown (NY), USA. 233 
g
 BC-2800Vet, MINDRAY, Mindray Co., Ltd. Shenzhen, China. 234 
h
 Cobas Mira, Roche Diagnostic, Basel, Switzerland. 235 
i
 DOP 2001, SAMED Elettromedicali srl, Merlino (LO), Italy. 236 
l
 MedCalc
®
, Version 11.3.0.0. 237 
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